Checkout
Cart: $0.00 - (0 items )

23andMe’s second act sits squarely in drug research and development

23andMe’s second act sits squarely in drug research and development



 The company first began making moves early in 2015, forging a partnership with Pfizer to conduct a bit of drug research using 23andMe’s genetic data. The pact was formed in the midst of orders from the Food and Drug Administration that 23andMe cease sales of its consumer health report product, which drove a major portion of both 23andMe’s revenue and brand awareness at the… Read More



Source: techCrunch

Back to top